Major advantages of 'early' administration of endocrine combination therapy in advanced prostate cancer

Clinical and Investigative Medicine

Volumn 16, Issue 6, 1993, Pages 493-498

  Labrie, F ^a   Dupont, A ^a   Cusan, L ^a   Gomez, J L ^a   Diamond, P ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

endocrine combination therapy; flutamide; LHRH agonist; prostate cancer

Indexed keywords

FLUTAMIDE; GONADORELIN AGONIST;

ARTICLE; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; FLUTAMIDE; GONADORELIN; HUMAN; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0027851316     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)